tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Angiofibroma D018322 2 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Mediastinitis D008480 2 associated lipids
Fibroadenoma D018226 2 associated lipids
Mucinoses D017520 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Oliguria D009846 2 associated lipids
Hutchinson's Melanotic Freckle D018327 2 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Anus Diseases D001004 3 associated lipids
Meningococcal Infections D008589 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Castleman Disease D005871 3 associated lipids
Scleritis D015423 3 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Digestive System Diseases D004066 3 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Ileus D045823 3 associated lipids
Anemia, Refractory D000753 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Pityriasis D010915 3 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Legionellosis D007876 3 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Perceptual Disorders D010468 3 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Lichen Planus D008010 3 associated lipids
Toxocariasis D014120 3 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Impetigo D007169 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Trichomonas Infections D014245 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Paronychia D010304 3 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Facial Neoplasms D005153 3 associated lipids
Gingivitis D005891 3 associated lipids
Hemophilia B D002836 3 associated lipids
Pouchitis D019449 3 associated lipids
Cryptococcosis D003453 3 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Pemphigus D010392 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Pterygium D011625 3 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Intestinal Atresia D007409 3 associated lipids
Foot Dermatoses D005533 3 associated lipids
Hyperkalemia D006947 3 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Immune System Diseases D007154 3 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Hematologic Diseases D006402 3 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Headache D006261 4 associated lipids
Pain, Intractable D010148 4 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Balanitis D001446 4 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Amenorrhea D000568 4 associated lipids
Blepharitis D001762 4 associated lipids
Diabetes Complications D048909 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Hallucinations D006212 4 associated lipids
Meningoencephalitis D008590 4 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Prurigo D011536 4 associated lipids
Viremia D014766 4 associated lipids
Gastroenteritis D005759 4 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Gout D006073 4 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Ovarian Cysts D010048 4 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Confusion D003221 4 associated lipids
Parotitis D010309 4 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Bone Diseases D001847 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gharpure VS et al. Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation. 1995 Bone Marrow Transplant. pmid:8547871
Koch K et al. CP-123,369: a potent, orally active immunosuppressive agent. 1995 Inflamm. Res. pmid:8548388
Lionetti P et al. Mucosal adaptation and destruction in response to lamina propria T cell activation in explants of human fetal intestine. 1995 Adv. Exp. Med. Biol. pmid:8525974
Ku YM et al. Compatibility of tacrolimus injection with cimetidine hydrochloride injection in 0.9% sodium chloride injection. 1995 Am J Health Syst Pharm pmid:8528874
Arreaza G et al. Expression of intercellular adhesion molecule-1 on human thyroid cells from patients with autoimmune thyroid disease: study of thyroid xenografts in nude and severe combined immunodeficient mice and treatment with FK-506. 1995 J. Clin. Endocrinol. Metab. pmid:8530625
Fruman DA et al. The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. 1995 J. Immunol. pmid:7530743
Braun W et al. Three-dimensional structure and actions of immunosuppressants and their immunophilins. 1995 FASEB J. pmid:7529736
Venkataraman L et al. FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells. 1995 J. Exp. Med. pmid:7532676
Zarnt T et al. Time-dependent inhibition of peptidylprolyl cis-trans-isomerases by FK506 is probably due to cis-trans isomerization of the inhibitor's imide bond. 1995 Biochem. J. pmid:7529995
Wang CR et al. T cell receptor-mediated signaling events in CD4+CD8+ thymocytes undergoing thymic selection: requirement of calcineurin activation for thymic positive selection but not negative selection. 1995 J. Exp. Med. pmid:7532685
Wera S et al. Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expression. 1995 FEBS Lett. pmid:7530217
Cao W et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. 1995 Transplantation pmid:7532879
Van Thiel DH et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. 1995 Am. J. Gastroenterol. pmid:7532912
Ning YM and Sanchez ER Stabilization in vitro of the untransformed glucocorticoid receptor complex of S49 lymphocytes by the immunophilin ligand FK506. 1995 J. Steroid Biochem. Mol. Biol. pmid:7532989
Fruman DA et al. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. 1995 Eur. J. Immunol. pmid:7533090
Cameron AM et al. Immunophilin FK506 binding protein associated with inositol 1,4,5-trisphosphate receptor modulates calcium flux. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7533300
Barkholt LM et al. New criteria for diagnosing cytomegalovirus hepatitis in liver transplant patients. 1995 Transplant. Proc. pmid:7533375
Jusko WJ et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). 1995 Ther Drug Monit pmid:8588229
Teraoka S et al. Effect of rescue therapy using FK 506 on relapsing rejection after combined pancreas and kidney transplantation. 1995 Transplant. Proc. pmid:7533381
Lohse DL et al. Insights derived from the structures of the Ser/Thr phosphatases calcineurin and protein phosphatase 1. 1995 Structure pmid:8590008
Fay JW et al. FK 506-based immunosuppression for prevention of graft versus host disease after unrelated donor marrow transplantation. 1995 Transplant. Proc. pmid:7533383
Murase N et al. Bone marrow augmentation for heart, liver, and small bowel transplantation: prolongation of graft survival and incidence of graft-versus-host disease. 1995 Transplant. Proc. pmid:7533386
Zeevi A et al. Serial evaluation of immune profiles of simultaneous bone marrow and whole organ transplant recipients. 1995 Transplant. Proc. pmid:7533388
Watanabe K et al. Factors influencing long-term operational tolerance in dogs treated with fractionated lymphoid irradiation, donor bone marrow cell infusion and FK506. 1995 Transplant. Proc. pmid:7533389
Wennberg L et al. Efficacy of various immunosuppressive drugs in preventing pig-to-rat islet xenograft rejection. 1995 Transplant. Proc. pmid:7533391
Tanaka M et al. Effect of anticomplement agent K-76 COOH in hamster-to-rat and guinea pig-to-rat xenotransplantation. 1995 Transplant. Proc. pmid:7533392
Tsugita M et al. Prevention of sensitization and hyperacute rejection in liver and heart xenografts by FK 506 plus donor antigens. 1995 Transplant. Proc. pmid:7533393
Ochiai T et al. Phase III study of FK 506 in kidney transplantation. Japanese FK 506 Study Group. 1995 Transplant. Proc. pmid:7533435
Scantlebury VP et al. Renal transplantation under cyclosporine and FK 506 for hemolytic uremic syndrome. 1995 Transplant. Proc. pmid:7533436
Hanafusa T et al. Long-term impact of hepatitis virus infection on kidney transplant recipients and a pilot study of the effects of interferon alpha on chronic hepatitis C. 1995 Transplant. Proc. pmid:7533440
Bundick RV et al. The effect of cyclosporin A, FK506, and rapamycin on the murine chronic graft-versus-host response--an in vivo model of Th2-like activity. 1995 Clin. Exp. Immunol. pmid:7533681
Hirakata Y et al. Influence of various immunosuppressive agents on the occurrence of endogenous bacteraemia in mice. 1995 J. Med. Microbiol. pmid:7533840
Gregory CR et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. 1995 Transplantation pmid:7533955
Egawa H et al. Isolated alkaline phosphatemia following pediatric liver transplantation in the FK506 ERA. 1995 Transplantation pmid:7533958
Tumlin JA et al. Expression of calcineurin activity and alpha-subunit isoforms in specific segments of the rat nephron. 1995 Am. J. Physiol. pmid:7485542
Furukawa F et al. FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice. 1995 Arch. Dermatol. Res. pmid:7487142
Lapa e Silva JR et al. Modulation of the bronchial inflammation in sensitized guinea-pigs by FK506, nedocromil sodium and dexamethasone. 1995 Eur. Respir. J. pmid:7489798
Schwaninger M et al. Involvement of the Ca(2+)-dependent phosphatase calcineurin in gene transcription that is stimulated by cAMP through cAMP response elements. 1995 J. Biol. Chem. pmid:7536740
Shackleton CR et al. Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. 1995 Transplantation pmid:7570950
Min Z and Jones NF Limb transplantation in rats: immunosuppression with FK-506. 1995 J Hand Surg Am pmid:7536766
Petrides AS [Do immunosuppressive agents really impair glucose tolerance in liver transplant patients?]. 1995 Z Gastroenterol pmid:7571761
Lyons WE et al. Neuronal regeneration enhances the expression of the immunophilin FKBP-12. 1995 J. Neurosci. pmid:7536825
Thomson AW and Bonham CA Inhibition of T lymphocyte activation and apoptotic cell death by cyclosporin A and tacrolimus (FK506). Its relevance to therapy of HIV infection. 1995 Adv. Exp. Med. Biol. pmid:7572394
Wortis HH et al. B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7536930
Paterson JM et al. Control of a novel adenylyl cyclase by calcineurin. 1995 Biochem. Biophys. Res. Commun. pmid:7575502
Bang H et al. Activation of Ca2+ signaling in neutrophils by the mast cell-released immunophilin FKBP12. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7536932
Cunningham EB The human erythrocyte membrane contains a novel 12-kDa inositolphosphate-binding protein that is an immunophilin. 1995 Biochem. Biophys. Res. Commun. pmid:7575593
Masaki Y et al. Cellular basis of acquired immunologic tolerance following total bowel transplantation in rats. I. Relation between donor lymphocyte chimerism and host-cell-mediated immunity. 1995 Transplant. Proc. pmid:7536971
Masaki Y et al. Cellular basis of immunologic tolerance following total bowel transplantation in rats. II. Dominant role of suppressor T cells in adoptive transfer of acquired tolerance to vascularized allografts. 1995 Transplant. Proc. pmid:7536972
Suzuki H et al. Spleen grafting might induce transplantation tolerance in rats. 1995 Transplant. Proc. pmid:7536973
Kawasaki M et al. [Immunosuppression and the problems in partial liver transplantation]. 1995 Nihon Rinsho Meneki Gakkai Kaishi pmid:8963785
Teraoka S et al. [Present status and problems in clinical application of tacrolimus(FK506)]. 1995 Nihon Rinsho Meneki Gakkai Kaishi pmid:8963787
Canzanello VJ et al. Renal sodium handling with cyclosporin A and FK506 after orthotopic liver transplantation. 1995 J. Am. Soc. Nephrol. pmid:7542491
Garrett-Engele P et al. Calcineurin, the Ca2+/calmodulin-dependent protein phosphatase, is essential in yeast mutants with cell integrity defects and in mutants that lack a functional vacuolar H(+)-ATPase. 1995 Mol. Cell. Biol. pmid:7542741
Baughman G et al. FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition. 1995 Mol. Cell. Biol. pmid:7542743
Pearlman DA and Connelly PR Determination of the differential effects of hydrogen bonding and water release on the binding of FK506 to native and Tyr82-->Phe82 FKBP-12 proteins using free energy simulations. 1995 J. Mol. Biol. pmid:7538591
Warty V et al. Tacrolimus analysis: a comparison of different methods and matrices. 1995 Ther Drug Monit pmid:7542809
Freeman DJ et al. Stability of FK 506 in whole blood samples. 1995 Ther Drug Monit pmid:7542810
Strumph P et al. The effect of FK506 on glycemic response as assessed by the hyperglycemic clamp technique. 1995 Transplantation pmid:7542815
Dumont FJ et al. Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma. 1995 Cell. Immunol. pmid:7538911
Sihra TS et al. A role for calcineurin (protein phosphatase-2B) in the regulation of glutamate release. 1995 Biochem. Biophys. Res. Commun. pmid:7542882
Theopold U et al. FKBP39, a Drosophila member of a family of proteins that bind the immunosuppressive drug FK506. 1995 Gene pmid:7538962
Zhao Y et al. Calcineurin activation protects T cells from glucocorticoid-induced apoptosis. 1995 J. Immunol. pmid:7539018
Bronsther O et al. Liver transplantation for HBV-related disease under immunosuppression with tacrolimus: an experience with 78 consecutive cases. 1995 J Okla State Med Assoc pmid:7539077
Chen J et al. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7539137
Renoir JM et al. Cyclosporin A potentiates the dexamethasone-induced mouse mammary tumor virus-chloramphenicol acetyltransferase activity in LMCAT cells: a possible role for different heat shock protein-binding immunophilins in glucocorticosteroid receptor-mediated gene expression. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7539138
Llull R et al. Multilineage amplification of graft-vs-host disease-resistant chimerism following rat vascularized bone marrow allotransplantation. 1995 Transplant. Proc. pmid:7544504
Hoshino H et al. Effects of FK506 on an experimental model of colitis in rats. 1995 Aliment. Pharmacol. Ther. pmid:7544633
Firdaous I et al. HPLC-microparticle enzyme immunoassay specific for tacrolimus in whole blood of hepatic and renal transplant patients. 1995 Clin. Chem. pmid:7544705
Ingels SC et al. Stability of FK506 (tacrolimus) in whole-blood specimens. 1995 Clin. Chem. pmid:7544707
Hikita N et al. Effects of topical FK506 on endotoxin-induced uveitis (EIU) in the Lewis rat. 1995 Curr. Eye Res. pmid:7540967
Takizawa H et al. Activated immunocompetent cells in rat colitis mucosa induced by dextran sulfate sodium and not complete but partial suppression of colitis by FK506. 1995 Digestion pmid:7544748
Cardenas ME et al. Targets of immunophilin-immunosuppressant complexes are distinct highly conserved regions of calcineurin A. 1995 EMBO J. pmid:7540976
Sher LS and Makowka L Immunosuppression: now we have choices. 1995 Hepatology pmid:7544759
Madsen KL et al. FK506 increases permeability in rat intestine by inhibiting mitochondrial function. 1995 Gastroenterology pmid:7540994
Perrot-Applanat M et al. The 59 kDa FK506-binding protein, a 90 kDa heat shock protein binding immunophilin (FKBP59-HBI), is associated with the nucleus, the cytoskeleton and mitotic apparatus. 1995 J. Cell. Sci. pmid:7544801
Yang WM et al. Cyclophilin A and FKBP12 interact with YY1 and alter its transcriptional activity. 1995 J. Biol. Chem. pmid:7541038
Hibi S et al. Severe rhabdomyolysis associated with tacrolimus. 1995 Lancet pmid:7544861
Kawamura A and Su MS Interaction of FKBP12-FK506 with calcineurin A at the B subunit-binding domain. 1995 J. Biol. Chem. pmid:7541044
Rao PN et al. Reduction of FK-506 requirements by combination with polyethylene glycol superoxide dismutase in orthotopic rat liver transplantation. 1995 J. Allergy Clin. Immunol. pmid:7541060
Gold BG et al. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. 1995 J. Neurosci. pmid:7472502
Takahara S and Okuyama A [Blood level monitoring of immunosuppressive agent]. 1995 Rinsho Byori pmid:7474422
Lauerma AI Immunomodulation of contact dermatitis. 1995 Curr. Probl. Dermatol. pmid:7587333
Cardenas ME et al. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. 1995 Curr. Opin. Nephrol. Hypertens. pmid:8591053
Wera S et al. Cyclosporin A, rapamycin and FK506 decrease prolactin release from rat pituitary cells in primary culture. 1995 Endocr. Res. pmid:7588431
Cameron AM et al. Calcineurin associated with the inositol 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux. 1995 Cell pmid:8521476
Stoller G et al. A ribosome-associated peptidyl-prolyl cis/trans isomerase identified as the trigger factor. 1995 EMBO J. pmid:7588623
Tamura K FK506: mechanism of immunosuppression and adverse-effects. 1995 J Toxicol Sci pmid:8531246
Farcasanu IC et al. Protein phosphatase 2B of Saccharomyces cerevisiae is required for tolerance to manganese, in blocking the entry of ions into the cells. 1995 Eur. J. Biochem. pmid:7588708
Mugiya S et al. Renal blood flow, fibrinolysis, and platelet aggregation following tacrolimus (FK 506) treatment in rats. 1995 Thromb. Res. pmid:8533130
Stemmer PM et al. Factors responsible for the Ca(2+)-dependent inactivation of calcineurin in brain. 1995 FEBS Lett. pmid:7589543
Kaplan A et al. The effects of cyclosporin A and FK506 on proliferation and IL-8 production of cultured human keratinocytes. 1995 J. Dermatol. Sci. pmid:8534611
Hadad SJ et al. FK 506: effects on glomerular hemodynamics and on mesangial cells in culture. 1995 Kidney Int. pmid:7564092
Zhu X et al. Enhancing and suppressive effects of immunosuppressants cyclosporin A, FK506, and KM2210 on the colony formation of murine bone marrow cells. 1995 Ann. Hematol. pmid:8534762
Mazur P et al. Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. 1995 Mol. Cell. Biol. pmid:7565718
Ockenfels HM et al. Tyrosine phosphorylation in psoriatic T cells is modulated by drugs that induce or improve psoriasis. 1995 Dermatology (Basel) pmid:8534940
Orengo CA et al. Structural similarity between the pleckstrin homology domain and verotoxin: the problem of measuring and evaluating structural similarity. 1995 Protein Sci. pmid:8535234
Ihara H et al. Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients--importance of trough level as a practical indicator. 1995 Int. J. Urol. pmid:8536129
Vilquin JT et al. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. 1995 Hum. Gene Ther. pmid:8573612
Sano T et al. FK506 and cyclosporin A inhibit granulocyte/macrophage colony-stimulating factor production by mononuclear cells in asthma. 1995 Eur. Respir. J. pmid:8575571